• Tenax Therapeutics on June 26, 2026 adopted a Change in Control Plan with double-trigger equity acceleration and cash severance for eligible employees.
• Plan pays only if termination without Cause or for Good Reason occurs up to three months before or within 12 months after a change in control.
• Also adopted a Severance Plan covering eligible employees terminated without Cause outside a change in control; cash severance varies by tenure and level.
• Amended employment agreements for Christopher Giordano, Thomas Staab, Stuart Rich to mirror plan economics; executives are excluded from both plans.
• Change-in-control terminations provide salary and benefits for 12 months, or 18 months for Giordano, annual bonus at 100% goals, equity vesting; release required.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-288600), on June 29, 2026, and is solely responsible for the information contained therein.